Related posts
Friday rally cap choppy weakU.S inflation hot, GDP cool, Wall Street down, TSX flatMicrosoft hits highs, markets riseThis summary was created by AI, based on 11 opinions in the last 12 months.
Experts have mixed opinions on Bristol Myers Squibb (BMY-N). Some are optimistic about the company's AI potential and strong dividend, while others express concerns about patent cliffs and the need for a turnaround. The company's recent acquisitions and partnerships in the pharmaceutical industry are seen as positive moves to address challenges. Despite differing views on the stock's performance, there is a consensus that it holds potential but also faces significant hurdles in the coming years.
Credit them for being a company which led to the schizophrenia drug, which the FDA just approved. BMY has been unloved, selling before 8x PE at a 4% dividend. Puzzling, but shares will certainly rise. He sold it last year and may re-enter it.
Pays over a 5% dividend. Was the top pharma, but slipped. Their purchase of Celgene disappointed while revenue growth has been negative. Earnings shrunk last year. But he likes the new CEO and him buying 3 companies in onocology and neuroscience, both growth areas. Also, there have been cost cuts. Be patient though. They reported a clean top and bottom line beat last week and issued very strong guidance. Trades at a cheap 7x 2025 PE.
It just raised its forecast, released better numbers than expected and revealed a slew of new, promising drugs. Shares have jumped. The new CEO knocked out of the park the latest numbers, instead of missing numbers as so often before.
They just reported a Q2 beat. It hasn't performed well, but is finally rebounding a little. Their product pipeline will be good for the next few years.
His whole mantra is to buy good companies that are getting better. He wants to have a strong fundamental view, and he wants the market to show that it's agreeing with him -- he doesn't want to be alone in the woods in a good market, not participating.
Problem is a fair bit of debt, low growth. In a market like this, you only need 20 companies to get a broadly diversified portfolio. Don't need to take on the risk of this one. Avoid.
It will need a lot of time to turn around. It hit bottom when it touched a 5.75% dividend yield. You won't see good news here until 2029 or 2030.
Dow 7% in May. Lots of struggle in the healthcare space. Will sell.
The market lacks patience for them to get into AI, though he disagrees and the dividend is good.
A lot of their big drugs are coming off patent, and they will need 5 years to turn around. Meanwhile, collect the 5% dividend as you wait. Be patient. He prefers Eli Lilly.
Down 23% in the past 6 months. Pays a 5% dividend. Be patient and give the current CEO a chance to turn things around.
Big on immune oncology and cardio. Technically doesn't look great, but eventually "the train will come along and collect the mail bag". Makes a ton of $$ in NA. Wide moat. Concerns about pipeline, but he thinks it's pretty good. Limited downside. Yield is 4.9%.
Good pricing power. Because products are so specialized, FDA puts them on sort of a fast track.
In the past quarter, They recently bought 3 companies, including Mirati, a small oncology company, and Karuna who may develop a wonder drug to treat schizophrenia. BMY needs to buy companies, because their top 3 drugs face steep patent cliffs, like a blood-clot drug, accounting for over 61% of 2023 (Jan-Sept)'s sales.
Bristol Myers Squibb is a American stock, trading under the symbol BMY-N on the New York Stock Exchange (BMY). It is usually referred to as NYSE:BMY or BMY-N
In the last year, 12 stock analysts published opinions about BMY-N. 7 analysts recommended to BUY the stock. 5 analysts recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Bristol Myers Squibb.
Bristol Myers Squibb was recommended as a Top Pick by on . Read the latest stock experts ratings for Bristol Myers Squibb.
Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.
12 stock analysts on Stockchase covered Bristol Myers Squibb In the last year. It is a trending stock that is worth watching.
On 2024-10-03, Bristol Myers Squibb (BMY-N) stock closed at a price of $54.2.
BMY paid nearly $13 billion to buy the company that was developing Cobenfy. This could could help BMY get the patent cliffs of their other drugs in a few years.